These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12623912)
1. Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes. Gami AS; Montori VM; Erwin PJ; Khan MA; Smith SA; BMJ; 2003 Mar; 326(7388):528-9. PubMed ID: 12623912 [No Abstract] [Full Text] [Related]
2. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Costa J; Borges M; David C; Vaz Carneiro A BMJ; 2006 May; 332(7550):1115-24. PubMed ID: 16585050 [TBL] [Abstract][Full Text] [Related]
3. Diabetes and lipids - a conundrum. Valabhji J; Robinson S Diabet Med; 2001 Mar; 18(3):250. PubMed ID: 11318849 [No Abstract] [Full Text] [Related]
5. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Haffner SM Diabetes Care; 1997 Apr; 20(4):469-71. PubMed ID: 9096961 [No Abstract] [Full Text] [Related]
6. Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used? Rowland Yeo K; Yeo WW Heart; 2002 May; 87(5):423-7. PubMed ID: 11997409 [TBL] [Abstract][Full Text] [Related]
7. Managing lipid disorders: further evaluation of the VA-HIT. Vajo Z; Reaven PD; Curr Diab Rep; 2003 Jun; 3(3):245-7. PubMed ID: 12762973 [No Abstract] [Full Text] [Related]
8. Lipid modification and coronary heart disease in type 2 diabetes: different from the general population? Feher MD; Elkeles RS Heart; 1999 Jan; 81(1):10-1. PubMed ID: 10220537 [No Abstract] [Full Text] [Related]
15. Benefits of lipid-lowering therapy. Stein JH; McBride P J Am Board Fam Pract; 1998; 11(5):423-4. PubMed ID: 9796776 [No Abstract] [Full Text] [Related]
16. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Pignone M; Phillips C; Mulrow C BMJ; 2000 Oct; 321(7267):983-6. PubMed ID: 11039962 [TBL] [Abstract][Full Text] [Related]
17. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Vakkilainen J; Steiner G; Ansquer JC; Perttunen-Nio H; Taskinen MR Diabetes Care; 2002 Mar; 25(3):627-8. PubMed ID: 11874962 [No Abstract] [Full Text] [Related]
18. Selections from current literature: the fight over fat: is pharmacological lipid lowering useful for coronary primary prevention? Green L Fam Pract; 1997 Oct; 14(5):411-5. PubMed ID: 9472378 [TBL] [Abstract][Full Text] [Related]
19. After the meta-analyses: a commentary on treatment of dyslipidaemia in the primary prevention of coronary heart disease. Silberberg JS Aust N Z J Med; 1994 Dec; 24(6):717-21. PubMed ID: 7717926 [No Abstract] [Full Text] [Related]
20. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications. Oparil S Hypertension; 2003 May; 41(5):1006-9. PubMed ID: 12695423 [No Abstract] [Full Text] [Related] [Next] [New Search]